GeoVax Labs, Inc. (GOVX) Balance Sheet

As reported in recent financial filings, GeoVax's total assets have contracted from $11.1 million in 2024Q3 to $3.0 million by 2026Q1, reflecting a rapid depletion of resources that underscores the company's inability to sustain its current research-heavy business model without consistent external capital injections.

Based on the most recent quarterly data, the current ratio has compressed to 1.06, indicating that GeoVax's ability to cover short-term obligations is increasingly constrained as cash reserves dwindle to $1.3 million, a level that appears insufficient to support long-term clinical development without immediate financing.

According to historical balance sheet data, the company's equity position has been severely eroded by accumulated deficits exceeding $156 million, a trend that highlights the long-term impact of sustained operating losses and the potential for future shareholder dilution to maintain basic corporate functions.